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Abstract
Introduction: Chemotherapy resistance resulting in incomplete pathologic response is associated with high risk of
metastasis and early relapse in breast cancer. The aim of this study was to identify and evaluate biomarkers of
treatment-resistant tumor cells.
Methods: We performed a cell surface marker screen in triple-negative breast cancer patient-derived xenograft
models treated with standard care genotoxic chemotherapy. Global expression profiling was used to further
characterize the identified treatment-resistant subpopulations.
Results: High expression of sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4) was found in residual tumor
cells surviving chemotherapy and in samples from metastatic patients who relapsed after neoadjuvant chemotherapy.
Gene and microRNA (miRNA) expression profiling linked SSEA4 positivity with a mesenchymal phenotype and a
deregulation of drug resistance pathways. Functional assays demonstrated a direct link between epithelial–mesenchymal
transition (EMT) and SSEA4 expression. Interestingly, SSEA4 expression, EMT, and drug resistance seemed to be regulated
posttranscriptionally. Finally, high expression of CMP-N-acetylneuraminate-β-galactosamide-α-2,3-sialyltransferase 2
(ST3GAL2), the rate-limiting enzyme of SSEA4 synthesis, was found to be associated with poor clinical outcome in breast
and ovarian cancer patients treated with chemotherapy.
Conclusions: In this study, we identified SSEA4 as highly expressed in a subpopulation of tumor cells resistant to multiple
commonly used chemotherapy drugs, as well as ST3GAL2, the rate-limiting enzyme of SSEA4 synthesis, as a predictive
marker of poor outcome for breast and ovarian cancer patients undergoing chemotherapy. Both biomarkers and
additionally identified regulatory miRNAs may be used to further understand chemoresistance, to stratify patient groups in
order to avoid ineffective and painful therapies, and to develop alternative treatment regimens for breast cancer patients.
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Introduction
Breast cancer is a heterogeneous disease at molecular
and cellular levels. Several subtypes of breast cancer can
be defined, depending on molecular marker expression
[1], and disease management is currently tailored ac-
cording to the molecular characteristics of each subtype.
Triple-negative breast cancer (TNBC) and the luminal B
subtype are characterized as very aggressive and associ-
ated with high risk of early relapse and metastasis [2, 3].
Owing to the lack of defined molecular targets for
TNBCs and due to the high proliferative rate of TNBCs
and luminal B tumors, chemotherapy remains a first-
choice therapeutic option for these two subtypes.
In the neoadjuvant setting, the standard options for
TNBC are a combination of doxorubicin/cyclophospha-
mide (AC) or 5-fluorouracil, epirubicin, and cyclophospha-
mide followed or not by taxane-containing regimens, or a
combination of cyclophosphamide, methotrexate, and 5-
fluorouracil [4]. The majority of TNBC patients respond
initially to neoadjuvant chemotherapy treatment, but only
about 20 % reach a pathological complete response,
whereas most patients either have lower de novo sensitivity
to chemotherapy or develop resistance to chemotherapy
[5]. Residual cancer cells persist and initiate tumor recur-
rence and metastasis within 3 years after chemotherapy in
about 40 % of patients [5]. Hence, the development of
predictive tests for chemotherapy resistance represents an
urgent need that would aid in therapy decision-making.
Many studies have been reported that provide data about
the molecular basis of human breast cancers. However, the
high degree of heterogeneity within the tumor, as well as
the varying response to chemotherapy of cellular subclones,
makes the interpretation of these molecular profiles diffi-
cult [6]. In particular, if biomarkers correlating with treat-
ment outcome are expressed only in subpopulations of
tumor cells, the analysis of bulk tumor material might lack
sensitivity. Furthermore, tumor cell subpopulations can
change their phenotype and gene expression profile to es-
cape chemotherapy by means of epithelial–mesenchymal
transition (EMT), upregulation of multidrug resistance
transporters, and modulation of key signaling pathways
[7, 8]. Thus, it is crucial to analyze marker expression pat-
terns at different time points during chemotherapy, when
the tumor cells are either developing drug resistance or de
novo resistant subpopulations are selected.
In the present study, we performed a flow cytometry–
based screen of cell surface markers in patient-derived
xenografts (PDXs) of TNBC tumor samples during AC
chemotherapy. PDXs exhibit morphology, molecular
characteristics, and drug response profiles similar to
those of the original patient tumors [9] and thereby rep-
resent a reliable model and a reproducible source for hu-
man tumor cells needed for detailed analyses of tumor
cell subpopulations over time [9, 10].
We observed that a high percentage of residual tumor
cells surviving chemotherapy at surgical ablation express
the sialyl-glycolipid stage-specific embryonic antigen 4
(SSEA4). Molecular profiling revealed mesenchymal
traits as well as upregulation of genes involved in
multidrug resistance in SSEA4-positive compared with
SSEA4-negative tumor cell subpopulations. Elevated
expression of CMP-N-acetylneuraminate-β-galactosamide-
α-2,3-sialyltransferase 2 (ST3GAL2), the enzyme catalyzing
the last step of SSEA4 synthesis, is associated with poor
prognosis in breast cancers treated with chemotherapy.
This predictive value was also confirmed in a cohort of
ovarian carcinoma. Thus, we propose SSEA4 as a novel
marker for EMT-associated chemotherapy resistance and
ST3GAL2 expression as a predictive marker for tumor
resistance to chemotherapy.
Methods
A detailed description of materials and methods can be
found in additional file 1.
Primary tissue material and xenotransplantation
Human breast cancer xenografts (HBCx) were estab-
lished from patient’s primary tumor surgical specimens
by grafting tumor fragments into the interscapular fat
pad and maintained through in vivo passages as previ-
ously described [9]. All experiments were performed in
accordance with French legislation concerning the pro-
tection of laboratory animals and in accordance with a
currently valid license issued by the French Ministry for
Agriculture and Fisheries for experiments on vertebrate
animals. The ethics committee was organized according
to the pertinent French legislation and was approved by
the French Ministry of Research under number CE 51.
Primary serous ovarian carcinoma cell lines were
established by transplantation of primary tumor speci-
men or tumor cells directly isolated from ascites or
pleural effusion samples. Human tumors were injected
intraperitoneally into NOD.Cg-Prkdcscid Il2rgtm1Wjl mice.
Engrafted first passage xenografts were dissociated into
single cells and maintained under serum-free culture
conditions. Animal care and all procedures were carried
out according to German legal regulations and were pre-
viously approved by the governmental review board of
the state of Baden-Wuerttemberg (Regierungspräsidium
Karlsruhe authorization number G17/12).
This study was performed with human tissue samples
obtained from patients admitted to the University Clinic
Mannheim Department of Gynecology. The study was
approved by the ethics committee of the University of
Heidelberg-Mannheim (case number 2011-380N-MA) and
conducted in accordance with the Declaration of Helsinki.
Written informed consent was obtained from all patients.
In addition, primary patient samples of clear cell renal cell
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carcinoma (RCC) were obtained from the Department of
Health Sciences at the University of Milan. All samples
were collected according to the regulations for the use of
primary material according to “doc. web n. 1878276” (Pub-
blicato sulla Gazzetta Ufficiale n. 72; 26 Mar 2012).
Cell lines used
The epithelial breast cell line MCF 10A was purchased
from the American Type Culture Collection (ATCC®
CRL-10317™; ATCC, Manassas, VA, USA). The HBCx-
17 and HBCx-39 cell lines were primary cells derived for
the respective HBCx tumors at XenTech SAS (Evry,
France). The OC-12, OC-14, OC-15, OC-18, OC-19, and
OC-20 cell lines were primary cells derived for the re-
spective ovarian cancer xenograft tumors at HI-STEM
gGmbH (Heidelberg, Germany).
Chemotherapeutic treatment
Doxorubicin (ADRIBLASTINA® RD; Pfizer, New York,
NY, USA) and cyclophosphamide (ENDOXAN®; Baxter
Healthcare, Deerfield, IL, USA) solutions were admin-
istered on the same day via intraperitoneal injection
at a dose of 2 mg/kg (doxorubicin) and 100 mg/kg
(cyclophosphamide). To obtain a complete response
for models HBCx-17 and HBCx-6, the same dose of
AC chemotherapy was applied a second time, 3 weeks
after the first injection. AC chemotherapy was applied
to 68 mice of tumor graft model HBCx-17, 32 mice
of HBCx-10, 35 mice of HBCx-6, and 30 mice of
HBCx-14 model, not including the control group.
Flow cytometry–based analysis
Tumor tissue was dissociated into a single-cell suspen-
sion using the human Tumor Dissociation Kit in com-
bination with the gentleMACS Octo Dissociator (both
from Miltenyi Biotec, Bergisch Gladbach, Germany) ac-
cording to the manufacturer’s instructions. Cells were
stained with the indicated antibodies (Additional file
2: Table S1) according to the manufacturer’s instruc-
tions and analyzed using the MACSQuant™ Analyzer
(Miltenyi Biotec) (Additional file 3: Figure S1). In the
cases of SSEA4, TRA-1-60, and TRA-1-81, recombin-
ant antibodies were available and were used because
of their superior characteristics [11, 12]. The specifi-
city of all recombinant antibodies was validated and
compared with conventional clones. In the case of
SSEA4, identical specificity for antibodies derived
from clone MC-813-70 and clone REA101 was proven
by cross- blocking experiments, which showed that ei-
ther antibody specifically blocks binding of the alter-
native one, suggesting that both antibodies bind the
same epitope on the target structure SSEA4 (Additional
file 4: Figure S2).
Isolation of SSEA4-positive and SSEA4-negative tumor cell
subpopulations
SSEA4-positive and SSEA4-negative tumor cell subpop-
ulations were isolated by magnetic activated cell sorting
(MACS® Technology; Miltenyi Biotec). After dissociation
and depletion of mouse cells using the Mouse Cell
Depletion Kit (Miltenyi Biotec), the cells were labeled
with SSEA4-phycoerythrin (Miltenyi Biotec) followed by
anti-phycoerythrin MicroBeads (Miltenyi Biotec) and
separated using MS and LD columns (Miltenyi Biotec).
For microarray analysis, cells were pelleted and lysed in
QIAzol® (QIAGEN, Hilden, Germany).
EMT induction
To induce EMT, the epithelial breast cell line MCF 10A
was treated with transforming growth factor (TGF)-β1
(Miltenyi Biotec) at concentrations of 10 and 20 ng/ml.
EMT markers such as epithelial cell adhesion molecule
(EpCAM), E-cadherin, vimentin, and fibronectin served
as indicators of EMT induction efficiency.
Microarray hybridization and data analysis
Messenger RNA (mRNA) and microRNA (miRNA)
expression profiling was performed using Agilent micro-
arrays (Agilent Technologies, Santa Clara, CA, USA)
according to the manufacturer’s instructions.
The mRNA and miRNA data discussed in this publica-
tion have been deposited in the National Center for Bio-
technology Information Gene Expression Omnibus (GEO)




To evaluate the prognostic value of candidate genes, the
publicly available Kaplan-Meier Plotter (http://kmplot.com/
analysis/) was used. The Kaplan-Meier survival plots of
the two patient cohorts were compared using log-
rank test with hazard ratios (HRs) and 95 % confi-
dence intervals [15, 16].
In vitro cytotoxicity assays
Cells were seeded in 96-well flat-bottom plates. After
2 days at 37 °C and 5 % CO2, the cells were treated
with different standard chemotherapy drugs. To obtain a
dose–response curve, each drug was tested at serial con-
centrations. Cell viability was analyzed 72 h after addition
of drugs using the CellTiter-Glo® Luminescent Cell Via-
bility Assay Kit (Promega, Madison, WI, USA) according
to the manufacturer’s instructions. Luciferase activity was
measured on a luminometer (PerkinElmer® EnVision™;
PerkinElmer, Waltham, MA, USA).
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Results
The expression of 23 cell surface markers in breast cancer
PDXs is affected by chemotherapy
An antibody screening based on a library of 45 anti-
bodies directed against surface epitopes including
published stem cell and/or cancer stem cell markers
(Additional file 2: Table S1) was performed to identify
novel biomarkers for breast cancer cell subpopulations
resistant to chemotherapeutic treatment. For the initial
screening, 50–100 xenografted mice were used for each
of four independent TNBC PDXs [9]. When tumor vol-
umes reached 150–350 mm3 (pretreatment stage), mice
were treated with an AC combination according to the
standard of care. After tumor shrinking to volumes of
14–63 mm3, the nodules were removed (residual tumor
stage). Tumors from untreated mice were removed
(untreated stage) to serve as direct controls. A group of
animals with residual tumors were kept until the disease
recurred (regrowth stage) (Fig. 1a). All tumors removed
at any time point were dissociated and analyzed by flow
cytometry. No significant differences concerning marker
expression were found between the pretreatment and
untreated stages, excluding size-dependent marker regu-
lation, whereas the expression of 10 markers decreased
(Fig. 1c) and the expression of 13 markers increased
(Fig. 1d) during chemotherapy. Eighty-seven percent (20
of 23) of these markers returned to an expression level
similar to the untreated stage upon tumor regrowth
(Fig. 1c and d). CD44 and CD133, which have been de-
scribed to correlate with a cancer stem cell and drug re-
sistance phenotype [17], showed enrichment in only one
of the four models. This is possibly due to the tumor
heterogeneity that characterizes patients’ tumors, which
was here well recapitulated by the use of PDX models
(Fig. 1d). However, we identified a distinct subpopulation
of tumor cells expressing SSEA4 that was strongly
enriched during chemotherapeutic treatment in all
tumor models analyzed. Independent replicates of three
tumor models confirmed significant enrichment in the
number of SSEA4-positive cells in residual tumors upon
AC treatment in all analyzed tumors (p < 0.001, n = 8 for
each tumor model) (Fig. 1e). This result was further con-
firmed by immunohistochemistry (Fig. 1b). Similarly to
other markers, the amount of SSEA4-positive cells de-
creased back to pretreatment levels in three of four
tumor models after the treatment was stopped.
To further address the correlation between CD24,
CD44, and SSEA4 expression, we performed containing
of these markers on residual tumor nodules after AC
chemotherapy and on untreated tumors of three inde-
pendent models (Additional file 5: Figure S3). We did
not observe a significant enrichment of the CD24low/
CD44high subpopulation in any of the models. In model
HBCx-6, there was a subpopulation of SSEA4+/CD44+
cells that was enriched by about twofold; however, the
SSEA4+/CD44− fraction was enriched to the same de-
gree. In models HBCx-10 and HBCx-14, CD44 and
SSEA4 expression was observed on separate subpopu-
lations. We concluded that SSEA4 expression is an
indicator of treatment-resistant cells that overcomes
the heterogeneity observed for the (cancer) stem cell
markers in the tumor models used in this study.
SSEA4 is a marker for de novo resistance to
chemotherapy treatment
In one PDX model, we observed tumors with variable
sensitivity to the AC treatment and noticed that the
amount of SSEA4-positive cells correlated with these
differences. Nineteen tumors showed reduced sensitivity
to AC treatment (tumor volume >100 mm3 as maximal
regression), and one tumor did not respond to the treat-
ment at all (no tumor shrinkage during treatment). The
percentages of SSEA4-positive cells were 36.8 % in sensi-
tive tumors, 42.2 % in tumors with reduced sensitivity,
and 98.5 % in the fully resistant tumor (data not shown).
Therefore, we compared tumors from PDX models that
are sensitive (n = 6) or de novo resistant (n = 4) to AC
treatment. Three of four resistant tumor models showed
higher percentages of SSEA4-positive cells than the six
sensitive tumors (Additional file 6: Figure S4).
To provide further evidence of resistance to drug tox-
icity, we established primary PDX-derived ex vivo cell
lines from tumors containing different amounts of
SSEA4-positive cells and treated them with chemothera-
peutic drugs in vitro. One of the cell lines derived from
model HBCx-17 showed reproducible growth as an ad-
herent culture and as a suspension culture, with cells
growing in suspension showing higher SSEA4 expression
than the adherent cells (Fig. 2a). In cytotoxicity assays
with seven commonly used drugs (Fig. 2b-f and data
not shown), the suspension cells showed higher half-
maximal inhibitory concentration values than the ad-
herent cells for the DNA synthesis and transcription
inhibitors cisplatin, mafosfamide, 5-fluorouracil, and
doxorubicin, indicating an increased resistance, but not
for the topoisomerase inhibitors etoposide, topotecan, and
irinotecan. To provide a dose-escalating reproduction of
our in vivo experiment, we treated an adherent cell line
derived from model HBCx-17, containing about 15 %
SSEA4-positive cells in the steady state, and analyzed the
phenotype of the cells surviving the treatment upon
administration of increasing drug dosages. In every
case, the surviving population showed a significantly
higher fraction of SSEA4-positive cells (Fig. 2g-i),
while the absolute number of SSEA4-positive cells was
not significantly increased.
Next, we evaluated possible differences in the tumori-
genic capacity of SSEA4-positive and SSEA4-negative
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Fig. 1 Identification of differentially regulated cell surface markers during chemotherapeutic treatment. a Study design for chemotherapy treatment
of xenograft tumors, blue circles around graphed points represent time points of analysis . b Immunohistochemical analysis of sialyl-glycolipid
stage-specific embryonic antigen 4 (SSEA4) expression (red, SSEA4; blue, 4′,6-diamidino-2-phenylindole). c, d The expression patterns of cell surface
markers in xenograft tumors from four individual breast cancer patients were analyzed by multiparametric flow cytometry during the course of
treatment. e The expression of SSEA4 during chemotherapeutic treatment of xenograft tumors was analyzed at four time points (n = 8). ***p <
0.001; scale bars = 300 μm for larger images and 100 μm for insets. A/C doxorubicin/cyclophosphamide, HBCx human breast cancer xenograft, TGFβR
transforming growth factor β receptor
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subpopulations in model HBCx-14, which shows about
10 % SSEA4-positive tumor cells when growing without
any treatment and a significant upregulation under gen-
otoxic stress. To do so, 105 freshly dissociated SSEA4-
positive or SSEA4-negative cells were injected into two
groups of eight mice each. Although a trend toward a
faster tumor initiation was observed when we grafted
the SSEA4-positive tumor subpopulation, both frac-
tions were able to generate tumors, indicating that
the positive fraction only has an initial growth advan-
tage (Additional file 7: Figure S5a). Furthermore, we
analyzed the expression of SSEA4 in tumors that
arose from both subpopulations. Whereas the fraction
of SSEA4-expressing cells in tumors that originated
from the SSEA4-negative subpopulation recovered to
around 5 %, the one from tumors that originated
from the SSEA4-positive subpopulation was reduced to
about 10 % following the growth phase in vivo (Additional
file 7: Figure S5b). The recovery of the original SSEA4-
positive versus SSEA4-negative ratio was also reflected
by the observation that when freshly dissociated
SSEA4-positive and SSEA4-negative cells were placed
Fig. 2 Expression of sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4) during chemotherapeutic treatment of breast cancer cells in vitro.
Human breast cancer xenograft (HBCx)-17 cells containing different amounts of SSEA4-positive cells were treated with chemotherapeutic drugs in
vitro (a). The half-maximal inhibitory concentration (IC50) values (n = 3) for the commonly used drugs cisplatin (b), mafosfamide (c), 5-fluorouracil (d),
and doxorubicin (Adriamycin/ADRIBLASTINA® RD) (e) were measured. The suspension cells showed higher IC50 values, indicating an increased
resistance to those drugs (f). To directly examine the phenotype of cells surviving the treatments, a purely adherent cell line derived from
model HBCx-17 was treated with increasing concentrations of mafosfamide (g), 4-hydroxycyclophosphamide (h), or doxorubicin (i) (n = 4). **p < 0.01,
***p < 0.001. ADH adherent culture, SUS suspension culture
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in culture separately, they restored the original positive
versus negative ratio within approximately 6 days (data
not shown), which correlated well with the observation
of SSEA4 downregulation during disease relapse after
chemotherapy.
SSEA4 expression is found in metastatic cells that
survived genotoxic chemotherapy
Local or metastatic breast cancer relapse may occur
many years after surgery, despite a short-term response
to neoadjuvant chemotherapy [18] or a failure of adju-
vant chemotherapy. To investigate SSEA4 expression in
metastatic relapse, we conducted a retrospective case
history study using PDXs derived from metastatic speci-
mens. These models were derived from confirmed M1-
stage patients through collection of liquid biopsies,
either peripheral circulating tumor cells (CTCs) or infil-
trating CTCs obtained from serous effusions [19]. Ro-
bust SSEA4 expression was exclusively found in PDXs
whose donors were previously treated with specific neo-
adjuvant chemotherapy formulations, including the AC
combination and other genotoxic drugs with analogous
modes of action, such as epirubicin (Fig. 3). Conversely,
metastatic patients who were administered taxols
(paclitaxel, docetaxel) or antimetabolites (capecitabine,
5-fluorouracil) as adjuvant therapy, but who had no gen-
otoxic treatment before sample collection (Fig. 3 and
Additional file 8: Table S2 for patient history), displayed
little or no expression of SSEA4 on their matched PDXs
(Fig. 3).
Molecular analysis of SSEA4-positive and SSEA4-negative
subpopulations
We performed microarray-based global mRNA and
miRNA expression profiling on SSEA4-positive and
SSEA4-negative cells using three independent TNBC
models: HBCx-6 (n = 7 tumors), HBCx-10 (n = 5 tu-
mors), and HBCx-14 (n = 9 tumors). To avoid a bias by
cells of murine origin [20], all mouse cells were depleted
after tumor dissociation (Fig. 4a) and SSEA4-positive
cells were labeled and magnetically separated from the
negative fraction (Fig. 4b) before expression profiling.
Transcripts with significantly increased (240 genes,
p < 0.05, ≥1.5-fold, Additional file 9: Table S3) or de-
creased (182 genes, p < 0.05, greater than or equal to
−1.5-fold, Additional file 9: Table S3) expression in
SSEA4-positive compared with SSEA4-negative cells
were subjected to a term enrichment analysis based on
Gene Ontology categories [21]. In the SSEA4-positive
fractions, we found a strong overrepresentation of genes
linked to the TGF-β and epidermal growth factor signaling
pathways as well as genes involved in cell adhesion and
migration and in regulation of apoptosis, proliferation,
and differentiation (Additional file 9: Table S3). Among
the genes upregulated across all tumor models, seven
functional groups involved in cellular import and export,
Fig. 3 Sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4) expression is found in metastatic cells that survived genotoxic chemotherapy.
a The surface expression of SSEA4 on primary cells from patient-matched xenografts (passages 1–3) was evaluated. Each xenograft was stained
with an isotype control (gray histogram) or with an SSEA4 antibody (blue histogram). b Quantification of SSEA4 expression on the cell surface of
six xenografts obtained from metastatic pleural effusions (PE) or circulating tumor cells (CTCs) from M1-stage metastatic breast cancer patients.
The median fluorescence intensity (MFI) ratio is calculated as the MFI of SSEA4-stained cells divided by the MFI of the isotype control-stained cells.
c Schematic overview of each metastatic breast cancer patient’s treatment characteristics. CT chemotherapy)
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Fig. 4 (See legend on next page.)
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response to toxins and oxidative stress were significantly
enriched (Additional file 9: Table S3). In particular, mem-
bers of the solute carrier (SLC) and multidrug resistance
ATP-binding cassette transporter families were signifi-
cantly upregulated (Additional file 10: Figure S6B).
Also, among the differentially expressed transcripts,
we identified a substantial number of genes involved in
EMT. Epithelial markers such as cytokeratin 19, CLDN1,
CLDN3, and CLDN4 showed lower expression in
SSEA4-positive cells, whereas mesenchymal indicators
such as fibronectin, vitronectin, ZEB1, and ZEB2 were
upregulated (Additional file 10: Figure S6 A). In contrast,
published stem cell markers were not consistently regu-
lated among the SSEA4-positive and SSEA4-negative cell
fractions (Additional file 10: Figure S6 C). As SSEA4 is a
glycolipid epitope, its expression cannot be monitored dir-
ectly by transcriptome profiling. SSEA3, the direct precur-
sor of SSEA4, showed no increased signal intensity in
SSEA4-positive cells when measured with anti-SSEA3
antibody in all analyzed models (data not shown). This in-
dicates that SSEA4 enrichment regulation may be due to
increased SSEA3-to-SSEA4 conversion or to increased
SSEA4 catabolism in SSEA4-negative cells. However, no
difference was observed in the expression of genes coding
for enzymes involved in degradation of SSEA4 or of
ST3GAL2, the enzyme catalyzing this final step of SSEA4
synthesis [22]. In expression analysis of the miRNA data
set, we identified 166 miRNAs more than twofold over-
represented and 68 miRNAs more than twofold underrep-
resented in SSEA4-positive versus SSEA4-negative cells
among all analyzed tumor models (Additional file 9: Table
S3). Hierarchical clustering of the Pearson correlation co-
efficients of our mRNA and miRNA expression datasets
showed a higher correlation of SSEA4-positive versus
SSEA4-negative phenotype in the miRNA rather than
mRNA data set (Fig. 4c). No miRNAs were signifi-
cantly upregulated, and 18 miRNAs were significantly
downregulated (p < 0.05 by paired t test), in SSEA4-
positive cells (Fig. 4d and Additional file 9: Table S3).
These results were independently validated by using a
flow cytometry–based 39-plex miRNA assay (Additional
file 11: Figure S7) for direct measurement of miRNAs
without prior amplification. To determine putative mRNA
targets for these candidates, we used six different computa-
tional target prediction tools and considered only targets
that were predicted by at least two target prediction algo-
rithms. On the basis of this analysis, 5 of the 18 miRNAs
downregulated in SSEA4-positive cells (miR-96-5p, miR-
200b-3p, miR-200c-3p, miR-429, and miR-92a-3p) are
predicted to target ST3GAL2, suggesting that SSEA4 ex-
pression is regulated posttranscriptionally. Furthermore,
12 of the 18 downregulated miRNAs are known to target
key mesenchymal regulator and indicator genes such as
ZEB1, ZEB2, fibronectin 1, Snail1, Snail2, and Twist
(Additional file 12: Figure S8 and Additional file 9:
Table S3).
SSEA4 expression is regulated by ST3GAL2
To provide functional confirmation of the role of
ST3GAL2 in the regulation of SSEA4 expression in PDX
samples, we knocked down ST3GAL2 by small interfer-
ing RNA (siRNA) in HBCx-39 cells, which show high
levels of SSEA4 expression, and analyzed the expression
of SSEA4. A significant decrease of SSEA4 expression
was observed upon ST3GAL2 expression inhibition
(p < 0.001, n = 6) (Fig. 5a and b). Knockdown of CD133
cell surface expression was used as a positive control for
siRNA targeting, and it had no impact on SSEA4 expres-
sion. To provide further evidence of the relationship
between ST3GAL2 and SSEA4, we compared ST3GAL2
mRNA levels with SSEA4 cell surface levels on nine differ-
ent tumor models, which showed significant positive
correlation (p < 0.002, Fig. 5c).
Epithelial–mesenchymal transition induces SSEA4
expression
As EMT has already been correlated with drug resist-
ance [23], we wanted to examine if SSEA4 expression
was increased after EMT induction. Upon treatment of
the epithelial breast cell line MCF 10A with TGF-β1,
almost all cells changed their morphology from an epi-
thelial to an elongated fibroblastic shape (Fig. 6a). As
expected [24], epithelial markers such as EpCAM and
E-cadherin were downregulated, while mesenchymal
markers such as vimentin and fibronectin were upreg-
ulated (Fig. 6a and data not shown). Upon EMT
(See figure on previous page.)
Fig. 4 Isolation and molecular analysis of sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4)-positive and SSEA4-negative tumor
subpopulations. a and b Flow cytometric analysis of cells before and after cell sorting. c Correlation matrices showing the relationship of
mRNA- and miRNA-based gene expression profiles in all experiments. Correlation coefficients are indicated by their color from 0.9 (black)
to 1.0 (yellow) for mRNA-based and from 0.75 (black) to 1.0 (yellow) for miRNA-based clustering. d Cluster analysis of miRNAs identified as
differentially expressed by discriminatory gene analysis in combination with a paired t test (p < 0.05) of the SSEA4-positive versus SSEA4-negative tumor
subpopulation. Resulting genes were grouped by similarities in gene expression patterns using hierarchical clustering (Pearson correlation,
average linkage). Levels of log2-transformed expression ratios are indicated from −3 (green) to 3 (red). FITC fluorescein isothiocyanate, FSC forward
scatter FSC-A forward scatter area, FSC-H forward scatter height, miRNA microRNA, mRNA messenger RNA, PE pleural effusions, PI propidium iodide,
SSC side scatter
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induction, the SSEA4-positive fraction increased more
than threefold, hence proving a causal correlation be-
tween the transition toward a mesenchymal pheno-
type and SSEA4 expression (Fig. 6b).
ST3GAL2 is a highly significant predictive and prognostic
marker in breast cancer patients
Given the functional connection between SSEA4 and
ST3GAL2, we evaluated the clinical value of ST3GAL2
in a large, publicly available clinical microarray data-
base of breast tumors from 2977 patients [15]. Highly
significant differences (p < 0.01) trending toward a
poorer outcome for patients expressing higher levels
of ST3GAL2 within the estrogen receptor–negative
(ER−) or ER−/progesterone receptor–negative (PR−)
subset of patients were found, independent of the
treatment (Fig. 7a). When we focused on patients
treated with chemotherapy, we observed a highly sig-
nificant reduction of relapse-free survival independent
from the tumor subtype (p < 0.01, HR 1.91) in ER−
patients (p < 0.01, HR 2.97) and in ER−/PR− patients
(p < 0.01, HR 3.08) among patients expressing high
levels of ST3GAL2 (Fig. 7b). When we applied distant
metastasis-free survival as an endpoint, we found that
patients expressing high levels of ST3GAL2 had a worse
outcome, confirming the involvement of SSEA4-positive
Fig. 5 Sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4) expression is regulated by CMP-N-acetylneuraminate-β-galactosamide-α-
2,3-sialyltransferase 2 (ST3GAL2). a Small interfering RNA (siRNA)–mediated knockdown of ST3GAL2 and ST3GAL3 significantly reduced the
expression of their respective target messenger RNAs (mRNAs), but not the housekeeping gene GAPDH, as measured by quantitative real-time
polymerase chain reaction. Each bar represents the expression intensity normalized to the Lipofectamine reagent (Life Technologies, Carlsbad,
CA, USA)-only control. b Knockdown of ST3GAL2 significantly reduced the expression of SSEA4, whereas targeting of CD133 or the close paralog
ST3GAL3 did not result in a significant change of SSEA4 expression. Knockdown of CD133 expression by the respective siRNA was used as
a positive control of direct targeting. Each bar represents the mean fluorescence intensity (MFI) normalized to the Lipofectamine-only control.
c Expression of ST3GAL2 mRNA was measured by two Affymetrix® (Affymetrix, Santa Clara, CA, USA) probes, 217650_x_at and 229336_at, in nine
tumor models and plotted against the frequency of SSEA4-positive cells as measured by flow cytometry in the respective models, which
showed a significant positive correlation. ***p < 0.001; ns = not significant; n = 6
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cells in metastasis formation (Fig. 7c), as observed in the
case of metastasis-derived PDXs.
SSEA4 and ST3GAL2 expression predict chemoresistance
and are associated with patient outcomes in other
carcinomas
To further evaluate SSEA4 expression as a marker of in-
trinsic tumor cell resistance to chemotherapy, we tested
SSEA4 expression in samples from primary clear cell
RCC, a tumor entity known to be de novo resistant to
chemotherapy in more than 95 % of patients [25] and
from late ovarian cancer, an aggressive disease whose
treatment relies on chemotherapy as the only thera-
peutic option [26]. Primary clear cell RCC as well as
healthy kidney tissues from the same patients were ana-
lyzed for SSEA4 expression. In all of the analyzed pa-
tients (n = 3), an elevated number of SSEA4-positive
cells was observed in the tumor tissue (Additional file
13: Figure S9). Similarly, when primary cells derived
from serous ovarian carcinoma specimens were analyzed
for expression of SSEA4, three of three samples from tu-
mors that previously received genotoxic treatment
showed SSEA4 expression above 10 %, whereas only one
primary cell line matched to treatment-naive patients
showed SSEA4 expression above 10 % (Fig. 8a–c). Ana-
lysis of mesenchyme-specific (FN1, SNAI1, ZEB2) and
epithelial (CLDN3) genes by quantitative real-time poly-
merase chain reaction revealed that ovarian cancer
primary cells with high SSEA4 expression showed higher
expression of mesenchyme-specific genes and lower ex-
pression of the epithelium-specific ones (Fig. 8a and b).
In light of these results, we evaluated whether
ST3GAL2 expression could be associated with pa-
tient prognosis in ovarian cancer. Using the whole
dataset of ovarian tumors from 1464 patients [16], a
significant difference trending toward a worse clinical
outcome was observed with respect to progression-
free survival (p < 0.05) as well as postprogression sur-
vival (p < 0.05) (Fig. 8e). When we assessed patients
treated with chemotherapy, the level of significance was
also strongly increased for both endpoints (p < 0.01)
(Fig. 8f).
Discussion
In the present study, we identified a novel subpopulation
of chemotherapy-resistant tumor cells defined by the ex-
pression of SSEA4, the highest-order glycosphingolipid
(GSL) in the globo series synthetic pathway starting
from glucosylceramide. Enrichment of SSEA4-positive
cells in residual tumors of all the tumor models used in
this study suggests that this pluripotency marker over-
comes the heterogeneity shown by many cancer stem
markers analyzed (e.g., CD44, CD133, CD117, CD271,
ABCG2) [27–29] that were found to be enriched only in
single models. A large body of evidence indicates
that upregulation of ceramide glycosylation by
Fig. 6 Epithelial–mesenchymal transition (EMT) induces sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4) expression. a The expression
of SSEA4 was evaluated upon EMT induction. Upon treatment, almost all cells changed their morphology from an epithelial to an elongated
fibroblastic shape. F-actin was stained with phalloidin to visualize the cytoskeleton architecture. The epithelial markers E-cadherin and epithelial
cell adhesion molecule (EpCAM) were downregulated, whereas the mesenchymal marker fibronectin was upregulated, upon stimulation. Scale
bar = 10 μm (first three columns at left) and 200 μm (right column). b The fraction of SSEA4-positive cells was increased upon EMT induction as
evaluated by flow cytometry. APC allophycocyanin, DAPI 4′,6-diamidino-2-phenylindole, TGFβ transforming growth factor β
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glucosylceramide synthase, through its ability to increase
levels of high-order GSLs, contributes to acquisition of
drug resistance in cancer cells [30]. In our experimental
model, the fraction of SSEA4-positive cells returned to
pretreatment levels in the majority of PDXs upon tumor
regrowth, indicating that this subpopulation has no gen-
eral growth advantage. Indeed, this behavior was pro-
posed for other subpopulations of drug-resistant cells
[31]. Accordingly, we did not observe a significant differ-
ence in tumorigenic capacity among SSEA4-positive or
SSEA4-negative subpopulations. Similar observations
have been made in non–small cell lung cancer, where re-
sidual tumor cells driving disease relapse after chemo-
therapy appear to be in an EMT state but do not show
any enrichment of cancer stem cell marker–positive cells
or enhanced tumor-initiating capacity [23]. Given that
Fig. 7 Expression of CMP-N-acetylneuraminate-β-galactosamide-α-2,3-sialyltransferase 2 (ST3GAL2) correlates with breast cancer patients’ prognosis.
The predictive value of ST3GAL2 was evaluated using a large, publicly available clinical microarray database based on breast tumors from
2977 patients [15]. Estrogen receptor–negative (ER−) patients and ER−/progesterone receptor –negative (PR−) patients displayed highly
significant differences (p < 0.01) trending toward a poorer prognosis for patients expressing higher levels of ST3GAL2 (a). When we focused
on patients treated with chemotherapy, we observed a highly significant reduction of relapse-free survival independent of the tumor
subtype [p < 0.01, hazard ratio (HR) 1.91] in ER− patients (p < 0.01, HR 2.97) and in double-negative patients (p < 0.01, HR 3.08) among patients
expressing high levels of ST3GAL2 (b). Also, when we applied distant metastasis-free survival as a primary endpoint, we found that patients
treated with chemotherapy had a worse prognosis when expressing high levels of ST3GAL2 (c).
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Fig. 8 (See legend on next page.)
Aloia et al. Breast Cancer Research  (2015) 17:146 Page 13 of 17
SSEA4-positive cell enrichment is a transient event, it is
possible that the SSEA4-positive and SSEA4-negative
cell balance tends to revert to the original ratio of posi-
tive and negative subpopulations observed in the un-
treated tumor during the latency period between cell
injection and macroscopic tumor growth.
Tumors with initially high levels of SSEA4-positive
cells seemed to be de novo resistant to chemotherapy.
One important question is whether SSEA4 is upregu-
lated during chemotherapy or if preexisting SSEA4-
positive cells are selected. The four TNBC PDXs used
for the antibody screening had been established from
untreated tumors and received a maximum of two cycles
of chemotherapy, whereas four to six cycles are adminis-
tered in the clinic. This might explain why PDXs from
metastatic breast cancer, as well as primary cells from
ovarian cancers, previously exposed to genotoxic therapy
show very high initial percentages of SSEA4-positive
cells. It is possible that this difference correlates with
reversible or irreversible enrichment of the SSEA4
population.
Molecular analysis suggested a higher correlation of
the drug resistance phenotype with the miRNA rather
than the mRNA expression profile. Among mRNAs
differentially expressed, a significant enrichment of
genes involved in cellular import and export, response
to toxins, and oxidative stress was observed, pathways
that are connected to drug response at least on a glo-
bal tumor level [32]. This is consistent with the re-
ported role of globo series GSLs in MDR1
upregulation via the activation of cSrc signaling [33].
One striking observation was the downregulation of
epithelial markers in conjunction with the overrepre-
sentation of mesenchymal markers [34] at the mRNA
level, and particularly, the concomitant downregula-
tion of their regulatory miRNAs. Sustaining the obser-
vation that SSEA4-positive tumor cells show a more
mesenchymal phenotype, we also found that induction of
EMT enhances SSEA4 expression. This is in concordance
with our observation that SSEA4 expression is found in
metastatic cells that survived genotoxic chemotherapy. A
large body of evidence connects EMT to drug resistance
[35, 36] and metastasis [37, 38], providing a mechanistic
explanation that might underlie the observed effects in
SSEA4-positive tumor cells.
Two of the differentially regulated miRNAs—miR-
141 and miR-200a—have been shown to influence re-
sistance to cisplatin and carboplatin in ovarian cancer
by controlling the oxidative stress response [39]. We
found that SSEA4 expression also correlates with a
mesenchymal state and drug resistance in ovarian
cancer.
Besides the EMT phenotype, the expression of
SSEA4 is also likely regulated by miRNAs among
different tumor subpopulations. The direct link be-
tween ST3GAL2 and SSEA4 was proven by siRNA-
mediated knockdown of ST3GAL2 resulting in a signifi-
cant decrease of SSEA4 expression and by positive cor-
relation between SSEA4 and ST3GAL2 expression in
PDX models. Interestingly, all five miRNAs predicted to
target ST3GAL2 are also directly involved in EMT and
drug resistance [39, 40]. Even if further studies clarify
whether ST3GAL2 is directly involved in drug resist-
ance, this regulatory mechanism, in combination with
the overexpression of resistance-associated genes, such
as transporters of the MDR family, might be the under-
lying mechanisms linking EMT and drug resistance to
SSEA4 expression.
Conclusions
We have identified SSEA4 to mark a subpopulation of
chemotherapy-resistant, mesenchymal breast cancer
cells. Furthermore, we have shown that the expression
level of ST3GAL2, the enzyme catalyzing SSEA4 synthe-
sis, can be used as a marker to predict clinical outcome
of breast and ovarian cancer patients, in particular those
treated with chemotherapy. SSEA4 and ST3GAL2 may
therefore represent key markers to classify patient
groups in order to avoid ineffective and painful therap-
ies and to develop alternative treatment regimens for
breast cancer patients.
(See figure on previous page.)
Fig. 8 Sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4) and CMP-N-acetylneuraminate-β-galactosamide-α-2,3-sialyltransferase 2
(ST3GAL2) expression in ovarian cancer cells correlates with a mesenchymal phenotype and patient prognosis. a Flow cytometric analyses
of SSEA4-phycoerythrin (red line) and respective isotype control (black line) on primary cells from patient-matched ovarian cancer cells.
Numbers indicate percentage of positive cells compared with the isotype control. b Quantification of SSEA4 expression on six patient-matched
primary ovarian cancer cell lines expressed as median fluorescence intensity (MFI) ratio. The MFI ratio is calculated as the MFI of SSEA4-stained
cells divided by the MFI of the respective isotype control-stained cells. c Overview of patient-derived ovarian cancer sample characteristics.
PE pleural effusion, TM treatment, FIGO International Federation of Gynecologists and Obstetricians. d Quantitative real-time polymerase chain
reaction analysis of genes related to mesenchymal (SNAI1, FN1, ZEB2) and epithelial (CLDN3) phenotypes in the six patient-matched primary
ovarian cancer cell lines. Error bars represent SD (performed in triplicates). ud undetected). e and f ST3GAL2 expression in ovarian cancer significantly
correlates with poor prognosis (e), particularly in patients who underwent chemotherapy (f). HR hazard ratio
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Additional files
Additional file 1: Supplemental experimental procedures. Detailed
description of materials and methods. (DOCX 62 kb)
Additional file 2: Table S1. Antibodies used for the screening
approach. Detailed description of used antibodies. (DOCX 46 kb)
Additional file 3: Figure S1. Representative gating strategy for flow
cytometry–based marker analysis of dissociated xenograft tumor tissue.
Tumor tissue was dissociated to obtain a single-cell suspension while
preserving cell surface epitopes. The sample was stained for mouse-specific
markers to exclude cells of murine origin from the analysis as well as for the
screening candidates and analyzed by multiparametric flow cytometry.
Doublets were excluded by forward scatter (FSC) area/FSC height
gating (a); debris was excluded by FSC/side scatter gating (b); dead
cells were excluded by gating off propidium iodide–positive events (c);
and mouse cells were excluded by gating on α-mouse-fluorescein
isothiocyanate–negative events (d). When we screened two samples
in parallel, we found that one of the samples was labeled using an
ultraviolet dye, allowing for subsequent separation of the events of
each sample by gating on the VioBlue channel fluorescence intensity
(e–h). (PNG 736 kb)
Additional file 4: Figure S2. Anti-SSEA4 antibodies derived from clone
REA101 and MC-813-70 recognize the same epitope. Flow cytometric
analysis of an antibody cross-blocking experiment on human induced
pluripotent stem cells. Cells were either directly fluorescently labeled
using anti-SSEA-4-phycoerythrin conjugates from clone REA101 (a) or
MC-813-70 (b) or after cells had been blocked by preincubation with
100 μg/ml unconjugated antibody of the alternative clone (a, b). The
fluorescent labeling of the REA101-derived anti-SSEA-4-phycoerythrin
antibody was strongly diminished by blocking with an excess of
MC-813-70 unconjugated antibody (a), while unconjugated REA101
caused a complete block of the fluorescent labeling of MC-813-70-
derived anti-SSEA-4-phycoerythrin antibody (b). These results indicate
that both antibodies recognize the same epitope and that the
REA101-derived antibody has a higher functional affinity than the
one derived from clone MC-813-70. (PNG 107 kb)
Additional file 5: Figure S3. Correlation among CD24-, CD44-, and
SSEA4-expressing subpopulations. To address the correlation between
CD24, CD44, and SSEA4 expression, we performed costaining of these
markers on residual tumor nodules after AC chemotherapy and untreated
tumors of three independent models: HBCx-6 (a), HBCx-10 (b), and
HBCx-14 (c). Regulation of the three markers did not correlate among
the treatment cycles. (PNG 1664 kb)
Additional file 6: Figure S4. Expression of SSEA4 in tumors responsive
or resistant to chemotherapeutic treatment. Tumors responsive (n = 6) or
resistant (n = 4) to AC treatment were analyzed for expression of SSEA4.
Three of the four resistant tumor models showed higher percentages of
SSEA4-positive cells than all of the six responsive tumors. In two of the
resistant tumor models, almost all of the cells expressed SSEA4. (TIFF 61 kb)
Additional file 7: Figure S5. Tumor-initiating capacity of the SSEA4-
positive and SSEA4-negative subpopulation. (a) One hundred thousand
freshly dissociated SSEA4-positive or SSEA4-negative cells were injected
in two groups of eight mice each. Tumor volume was measured once
per week, and the mean volume of both groups was calculated. The
significance level (p value by t test) is indicated above each time
point. (b) The frequency of SSEA4-expressing cells in the parental
tumor model HBCx-14 and in tumors that originated from the SSEA4-
positive or SSEA4-negative subpopulation was determined by flow
cytometry, which indicated a regulation of SSEA4 expression back to
the initial level during the growth phase in vivo. (PNG 93 kb)
Additional file 8: Table S2. Treatment history of breast cancer patients.
Detailed description of treatment history of breast cancer patients. (XLSX 11 kb)
Additional file 9: Table S3. Results of microarray analysis. Results of
gene and miRNA expression profiling, Gene Ontology analysis, and
miRNA target prediction. (XLSX 118 kb)
Additional file 10: Figure S6. SSEA4-positive breast cancer cells show
differential expression of genes pointing toward a mesenchymal state as
well as increased expression of members of the SLC and multidrug
resistance ATP-binding cassette transporter families, but not of stem
cell associated transcripts. (a) In the SSEA4-positive cell fraction,
genes characteristic of an epithelial state showed decreased expression
compared with the SSEA4-negative fraction. In contrast, genes characteristic
of a mesenchymal state showed increased expression compared with the
SSEA4-negative fraction. (b) In the SSEA4-positive cell fraction, members of
the SLC and multidrug resistance ATP-binding cassette transporter families
showed increased expression compared with the SSEA4-negative fraction.
(c) Stem cell markers were not consistently regulated among the SSEA4-
positive and SSEA4-negative cell fractions. The housekeeping gene
GAPDH showed no significant regulation among the subpopulations.
Each bar represents the log2 expression ratio of the SSEA4-positive
fraction relative to the SSEA4-negative fraction for the respective
tumor model. (TIFF 655 kb)
Additional file 11: Figure S7. Validation of miRNA candidates using
a flow cytometry–based 39-plex miRNA assay. (a) Cluster analysis of
expression ratios (log2-transformed) obtained from hybridization of
SSEA4-positive (pos) and SSEA4-negative (neg) samples. The miRNAs
that were significantly downregulated in SSEA4-positive cells based on
the microarray analysis are highlighted with a blue bar. (b) Comparison
of miRNA bead assay (BA) and microarray data (MA; average of all three
samples). Seven miRNAs that were differentially expressed between
SSEA4-positive and SSEA4-negative cells, as well as three miRNAs
(miR-30b-5p, miR-29a-3p, and miR-16-5p) expressed at a similar level
in both cell types, are shown. The bead assay results correlated well
with the microarray data. (PNG 509 kb)
Additional file 12: Figure S8. SSEA4-positive breast cancer cells show
decreased expression of miRNAs inhibiting EMT inducers. Expression
ratios of the 12 miRNAs targeting the key mesenchymal regulator and
indicator genes ZEB1, ZEB2, fibronectin 1, Snail1, Snail2, and Twist. Each
bar represents the log2 expression ratio of the SSEA4-positive fraction
relative to the SSEA4-negative fraction for the respective tumor model.
(TIFF 201 kb)
Additional file 13: Figure S9. Expression of SSEA4 in RCC and healthy
kidney tissue. Primary RCC and healthy kidney tissues from the same
patient were dissociated and analyzed by multiparametric flow
cytometry. Doublets were excluded by FSC-A/FSC-H gating (a); debris
was excluded by FSC/SSC gating (b); dead cells were excluded by
gating off PI+ events (c); and lineage-positive cells were excluded by
gating on α-Lin-FITC–negative events (d). In each patient, healthy and
tumor tissues were analyzed in parallel in one labeling reaction.
Therefore, one of the samples was labeled using a UV dye, allowing
for subsequent separation of the events of each sample by gating on
the VioBlue channel fluorescence intensity (e–h). In all of the analyzed
patients (n = 3), the expression of SSEA4 was strongly increased in the
tumor tissue as compared with the respective healthy tissue, with
almost all tumor cells expressing SSEA4 in two of the patients (f–h).
*α-Lin-FITC = CD45-FITC, CD31-FITC, CD235a (glycophorin A)-FITC.
(PNG 717 kb)
Abbreviations
AC: doxorubicin/cyclophosphamide; APC: allophycocyanin; CT: chemotherapy;
CTC: circulating tumor cell; DAPI: 4′,6-diamidino-2-phenylindole; EMT: epithelial–
mesenchymal transition; EpCAM: epithelial cell adhesion molecule; ER: estrogen
receptor; FIGO: International Federation of Gynecologists and Obstetricians;
FITC: fluorescein isothiocyanate; FSC: forward scatter; FSC-A: forward scatter
area; FSC-H: forward scatter height; GEO: Gene Expression Omnibus;
GSL: glycosphingolipid; HBCx: human breast cancer xenograft; IC50: half-
maximal inhibitory concentration; MFI: median fluorescence intensity;
miRNA: microRNA, mIR; mRA: messenger RNA; PDX: patient-derived
xenograft; PE: pleural effusion; PI: propidium iodide; PR: progesterone
receptor; RCC: renal cell carcinoma; siRNA: small interfering RNA; SSC: side
scatter; SSEA4: sialyl-glycolipid stage-specific embryonic antigen 4;
ST3GAL2: CMP-N-acetylneuraminate-β-galactosamide-α-2,3-sialyltransferase 2;
TGF: transforming growth factor; TM: treatment; TNBC: triple-negative
breast cancer.
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